Replies to post #5001 on Amarin Corp Plc (AMRN)

[stangish]

They are public...Read There SEC filings...

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001047469-13-004295%2Etxt&FilePath=%5C2013%5C04%5C12%5C&CoName=OMTHERA+PHARMACEUTICALS%2C+INC%2E&FormType=424B4&RcvdDate=4%2F12%2F2013&pdf=

Page 2

There not even going after the anchor indication at this time!

After commercially launching Epanova in the severe hypertriglyceridemia indication, we will consider pursuing the development and commercialization of Epanova in combination with statins as a therapy for non-HDL-C and triglyceride reduction in high cardiovascular risk patients with high triglycerides, as well as other indications. Under the SPA for our ESPRIT study, we are able to submit a supplemental NDA for an indication for Epanova for the reduction of non-HDL-C and triglycerides in patients with high triglycerides in combination with statin therapy after we obtain approval for Epanova for patients with severe hypertriglyceridemia and are substantially underway with a cardiovascular outcomes study. While we do not intend to immediately pursue such an outcomes study and, therefore, be able to submit a supplemental NDA for this indication, we will review our strategy with respect to this second indication in light of Epanova's commercial success in severe hypertriglyceridemia and our ability to find a suitable pharmaceutical partner to enter into a development and commercial collaboration.